433 related articles for article (PubMed ID: 18425988)
1. The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care.
García-Rodríguez LA; Massó-González EL; Wallander MA; Johansson S
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):943-52. PubMed ID: 18425988
[TBL] [Abstract][Full Text] [Related]
2. The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases.
García-Rodríguez LA; González-Pérez A; Stang MR; Wallander MA; Johansson S
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):953-61. PubMed ID: 18425987
[TBL] [Abstract][Full Text] [Related]
3. Results from a rosuvastatin historical cohort study in more than 45,000 Dutch statin users, a PHARMO study.
Goettsch WG; Heintjes EM; Kastelein JJ; Rabelink TJ; Johansson S; Herings RM
Pharmacoepidemiol Drug Saf; 2006 Jul; 15(7):435-43. PubMed ID: 16761304
[TBL] [Abstract][Full Text] [Related]
4. Use of multiple international healthcare databases for the detection of rare drug-associated outcomes: a pharmacoepidemiological programme comparing rosuvastatin with other marketed statins.
García Rodríguez LA; Herings R; Johansson S
Pharmacoepidemiol Drug Saf; 2010 Dec; 19(12):1218-24. PubMed ID: 20922707
[TBL] [Abstract][Full Text] [Related]
5. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy.
McAfee AT; Ming EE; Seeger JD; Quinn SG; Ng EW; Danielson JD; Cutone JA; Fox JC; Walker AM
Pharmacoepidemiol Drug Saf; 2006 Jul; 15(7):444-53. PubMed ID: 16761308
[TBL] [Abstract][Full Text] [Related]
6. Rosuvastatin safety: lessons from the FDA review and post-approval surveillance.
Davidson MH
Expert Opin Drug Saf; 2004 Nov; 3(6):547-57. PubMed ID: 15500414
[TBL] [Abstract][Full Text] [Related]
7. Predictors and outcomes of increases in creatine phosphokinase concentrations or rhabdomyolysis risk during statin treatment.
van Staa TP; Carr DF; O'Meara H; McCann G; Pirmohamed M
Br J Clin Pharmacol; 2014 Sep; 78(3):649-59. PubMed ID: 24602118
[TBL] [Abstract][Full Text] [Related]
8. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
Kostapanos MS; Milionis HJ; Elisaf MS
Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
[TBL] [Abstract][Full Text] [Related]
9. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases.
Dormuth CR; Hemmelgarn BR; Paterson JM; James MT; Teare GF; Raymond CB; Lafrance JP; Levy A; Garg AX; Ernst P;
BMJ; 2013 Mar; 346():f880. PubMed ID: 23511950
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and drug utilization patterns of new users of rosuvastatin and other statins in four countries.
McAfee AT; Rodríguez LA; Goettsch WG; González-Pérez A; Johansson S; Ming EE; Wallander MA; Herings RM
Minerva Cardioangiol; 2010 Dec; 58(6):611-22. PubMed ID: 21135803
[TBL] [Abstract][Full Text] [Related]
11. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program.
Shepherd J; Vidt DG; Miller E; Harris S; Blasetto J
Cardiology; 2007; 107(4):433-43. PubMed ID: 17363845
[TBL] [Abstract][Full Text] [Related]
12. Myopathy caused by a combination rosuvastatin and fenofibrate.
Dedhia V; Munsi SC
J Assoc Physicians India; 2007 Feb; 55():152-3. PubMed ID: 17571748
[No Abstract] [Full Text] [Related]
13. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance.
Kennedy SP; Barnas GP; Schmidt MJ; Glisczinski MS; Paniagua AC
J Clin Lipidol; 2011; 5(4):308-15. PubMed ID: 21784377
[TBL] [Abstract][Full Text] [Related]
15. McArdle disease with rhabdomyolysis induced by rosuvastatin: case report.
Lorenzoni PJ; Silvado CE; Scola RH; Luvizotto M; Werneck LC
Arq Neuropsiquiatr; 2007 Sep; 65(3B):834-7. PubMed ID: 17952291
[TBL] [Abstract][Full Text] [Related]
16. Rosuvastatin: winner in the statin wars, patients' health notwithstanding.
Wolfe S
BMJ; 2015 Mar; 350():h1388. PubMed ID: 25787130
[No Abstract] [Full Text] [Related]
17. Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy.
Danik JS; Chasman DI; MacFadyen JG; Nyberg F; Barratt BJ; Ridker PM
Am Heart J; 2013 Jun; 165(6):1008-14. PubMed ID: 23708174
[TBL] [Abstract][Full Text] [Related]
18. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.
Mora S; Glynn RJ; Hsia J; MacFadyen JG; Genest J; Ridker PM
Circulation; 2010 Mar; 121(9):1069-77. PubMed ID: 20176986
[TBL] [Abstract][Full Text] [Related]
19. Rosuvastatin in older patients with systolic heart failure.
Kjekshus J; Apetrei E; Barrios V; Böhm M; Cleland JG; Cornel JH; Dunselman P; Fonseca C; Goudev A; Grande P; Gullestad L; Hjalmarson A; Hradec J; Jánosi A; Kamenský G; Komajda M; Korewicki J; Kuusi T; Mach F; Mareev V; McMurray JJ; Ranjith N; Schaufelberger M; Vanhaecke J; van Veldhuisen DJ; Waagstein F; Wedel H; Wikstrand J;
N Engl J Med; 2007 Nov; 357(22):2248-61. PubMed ID: 17984166
[TBL] [Abstract][Full Text] [Related]
20. Incidence of skeletal muscle disorders after statins' treatment: consequences in clinical and EMG picture.
Drobny M; Pullmann R; Odalos I; Skerenova M; Saniova B
Neuro Endocrinol Lett; 2014; 35(2):123-8. PubMed ID: 24878976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]